Literature DB >> 17008169

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales.

Caroline L Trotter, Mary E Ramsay, Stephen Gray, Andrew Fox, Edward Kaczmarski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17008169     DOI： 10.1016/S1473-3099(06)70584-9

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  17 in total

1.  Impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia.

Authors:  Tung Siu; Wrency Tang; Meenakshi Dawar; David M Patrick
Journal:  Can J Public Health       Date:  2008 Sep-Oct

2.  Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.

Authors:  Peter C Fusco; Esmé K Farley; Chun-Hsien Huang; Samuel Moore; Francis Michon
Journal:  Clin Vaccine Immunol       Date:  2007-03-21

Review 3.  Epidemiological profile of meningococcal disease in the United States.

Authors:  Lee H Harrison
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

4.  Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection.

Authors:  Nicole Le Saux; Julie A Bettinger; Susan Wootton; Scott A Halperin; Wendy Vaudry; David W Scheifele; Raymond Tsang
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

5.  Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005.

Authors:  Lee H Harrison; Kathleen A Shutt; Susanna E Schmink; Jane W Marsh; Brian H Harcourt; Xin Wang; Anne M Whitney; David S Stephens; Amanda A Cohn; Nancy E Messonnier; Leonard W Mayer
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

Review 6.  Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

Authors:  Caroline L Trotter; Martin C J Maiden
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

7.  Bacterial Meningitis in Brazil: Baseline Epidemiologic Assessment of the Decade Prior to the Introduction of Pneumococcal and Meningococcal Vaccines.

Authors:  Luciano Cesar Pontes Azevedo; Cristiana M Toscano; Ana Luiza Bierrenbach
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

8.  Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.

Authors:  Hiltsje Hepkema; Koen B Pouwels; Arie van der Ende; Tjalke A Westra; Maarten J Postma
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

9.  Global optimal eBURST analysis of multilocus typing data using a graphic matroid approach.

Authors:  Alexandre P Francisco; Miguel Bugalho; Mário Ramirez; João A Carriço
Journal:  BMC Bioinformatics       Date:  2009-05-18       Impact factor: 3.169

10.  Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme.

Authors:  G L Lawrence; H Wang; M Lahra; R Booy; P B McINTYRE
Journal:  Epidemiol Infect       Date:  2016-04-20       Impact factor: 4.434
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.